GlaxoSmithKline news from FiercePharma
NewsGSK accused of monopolizing Wellbutrin
Did GlaxoSmithKline try to monopolize the Wellbutrin market? A lawsuit now certified as class-action says so. The plaintiffs accuse GSK of artificially boosting Wellbutrin prices by fibbing to the Read more...
Glaxo bonds bring whopping $9B
GlaxoSmithKline went hat in hand to the bond markets and came back with a record $9 billion. Intending to sell $6 billion in corporate bonds, GSK added $3 billion more as investors hungry for Read more...
Pharma CEOs mull industry "trust deficit'
We love it when pharma CEOs depart from their usual talking points about financial results and restructurings and pipelines, to wax philosophical on their place in the word. This week, we heard an Read more...
ALSO NOTED: Novo Nordisk creating 400 NJ jobs; Schering to sell off animal products;
> GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company. Read more...
GSK, Schering-Plough profits drop
When big drugs tank, they take their makers down with them. Witness first-quarter reports from GlaxoSmithKline and Schering-Plough. GSK is suffering on a Read more...
ALSO NOTED: Bayer sues Watson over Yasmin; Zimmer weeds out doc conflicts
> Open another chapter in the Bayer fight to protect Yasmin patents: Watson Pharmaceuticals filed for FDA approval for its copycat version of the birth control pill, and Bayer sued to keep the Read more...
FDA probe clears generic Wellbutrin
Listen to all those generics makers heaving sighs of relief. The FDA has given the thumbs-up to Teva's generic Wellbutrin XL, which has been under investigation since early last year. Patients who'd Read more...
Indian drug market ballooning
If you had any doubt why Pfizer, GlaxoSmithKline, and other Big Pharma companies are drooling over business in the Read more...
| Press ReleasesGlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... PRESS RELEASE: GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breas GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases Data on abstract 6076 embargoed until Sunday 16 December Read more... PRESS RELEASE: GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay PHILADELPHIA, Dec. 17 -- GlaxoSmithKline announced today that it has received a complete response letter Read more... |
Get more GlaxoSmithKline coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight